Protagonist Therapeutics, Inc.
ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES
Last updated:
Abstract:
Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
Status:
Application
Type:
Utility
Filling date:
28 Jan 2021
Issue date:
25 Nov 2021